Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

7.47B

Market cap7.47B

Price-Earnings ratio

198.54

Price-Earnings ratio198.54

Dividend yield

—

Dividend yield—

Average volume

1.03M

Average volume1.03M

High today

$69.82

High today$69.82

Low today

$68.04

Low today$68.04

Open price

$68.57

Open price$68.57

Volume

775.01K

Volume775.01K

52 Week high

$91.00

52 Week high$91.00

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $69.00. The company's market cap stands at 7.47B, with a P/E ratio of 198.54.

As of 2026-05-30, Corcept Therapeutics(CORT) stock has fluctuated between $68.04 and $69.82. The current price stands at $69.00, placing the stock +1.4% above today's low and -1.2% off the high.

Corcept Therapeutics(CORT) shares are trading with a volume of 775.01K, against a daily average of 1.03M.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $91.00 at its peak.

CORT News

TipRanks 19h

Top Corcept Executive Makes Notable Move With Fresh Stock Sale

New insider activity at Corcept Therapeutics ( (CORT) ) has taken place on May 29, 2026. Unlock trusted, data-backed investing tools with TipRanks Premium, fro...

Investing.com 22h

Corcept endocrinology president Sean Maduck sells $4.9m in stock - Investing.com

...

Simply Wall St 2d

A Look At Corcept Therapeutics Valuation As Relacorilant NDA Resubmission Advances Toward FDA Decision

Corcept Therapeutics (CORT) has put relacorilant for Cushing’s syndrome back in front of the FDA, planning to resubmit its New Drug Application after additional...

Analyst ratings

83%

of 6 ratings

Buy

83.3%

Hold

16.7%

Sell

More CORT News

TipRanks 2d

Corcept stockholders approve expanded incentive plan and board

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 2d

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $135 from $110 and keeps a Buy rating on the shares. The firm Corcept surprised today...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Robinhood Markets

Palantir Technologies

Spotify

Gilead Sciences

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.